UNCLAIMED
Science 37
Overview
Science 37 operates within the Computers and Technology and Biotech industries, specializing in direct-to-patient clinical trial solutions. The company focuses on addressing challenges in patient recruitment and retention for clinical studies, particularly in rare diseases and conditions requiring extensive monitoring. Through its FDA-inspected Direct-to-Patient Site model, Science 37 provides in-home visits conducted by research-grade nurses, facilitating data collection and participant engagement while minimizing the burden of traditional site visits. Their case studies highlight successful enrollment strategies for various trials, including those for Vascular Ehlers-Danlos Syndrome, Cholestatic Pruritus, and Atrial Fibrillation, where they have demonstrated accelerated enrollment timelines and improved participant retention through innovative remote trial designs. Science 37’s approach leverages technology and patient advocacy networks to enhance trial accessibility, ensuring compliance with complex protocol requirements while maintaining high standards of safety and data integrity. The company aims to streamline clinical research processes, ultimately contributing to the advancement of medical knowledge and treatment options.